Profile data is unavailable for this security.
About the company
Cytokinetics, Incorporated is a late-stage, specialty cardiovascular biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which cardiac muscle performance is compromised. The Company specializes in muscle biology and the mechanics of muscle performance. It is developing small molecule drug candidates specifically engineered to impact myocardial muscle function and contractility. Its cardiac muscle contractility program is focused on the cardiac sarcomere. Its clinical-stage drug candidates are: aficamten, which is a next-in-class cardiac myosin inhibitor; omecamtiv mecarbil, which is a cardiac myosin activator; CK-586, which is an additional cardiac myosin inhibitor, and CK-136, which is a cardiac troponin activator. CK-586 is designed to reduce the hypercontractility associated with heart failure with preserved ejection fraction.
- Revenue in USD (TTM)3.75m
- Net income in USD-530.60m
- Incorporated1997
- Employees423.00
- LocationCytokinetics Inc350 Oyster Point BoulevardSOUTH SAN FRANCISCO 94080United StatesUSA
- Phone+1 (650) 624-3000
- Fax+1 (650) 624-3010
- Websitehttps://cytokinetics.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apellis Pharmaceuticals Inc | 524.07m | -417.27m | 5.01bn | 702.00 | -- | 18.79 | -- | 9.57 | -3.46 | -3.46 | 4.33 | 2.20 | 0.5788 | 0.5747 | 3.50 | 746,538.40 | -46.09 | -73.88 | -57.28 | -90.03 | 86.47 | -- | -79.62 | -326.49 | 3.02 | -39.71 | 0.6087 | -- | 425.83 | -- | 18.94 | -- | -- | -- |
| Immunitybio Inc | 302.00k | -600.96m | 5.29bn | 628.00 | -- | -- | -- | 17,518.20 | -1.05 | -1.05 | 0.0005 | -1.02 | 0.0008 | -- | 0.1677 | 480.89 | -161.65 | -112.76 | -946.50 | -316.07 | -- | -- | -199,138.70 | -37,700.74 | -- | -1.92 | 5.32 | -- | 159.17 | 67.62 | -40.00 | -- | 18.48 | -- |
| Ionis Pharmaceuticals Inc | 776.62m | -384.77m | 5.45bn | 927.00 | -- | 18.35 | -- | 7.01 | -2.67 | -2.67 | 5.40 | 2.03 | 0.275 | 0.379 | 81.52 | 837,777.80 | -13.62 | -6.30 | -15.20 | -7.44 | 98.72 | 98.75 | -49.54 | -21.23 | 7.28 | -- | 0.8114 | -- | 34.10 | 5.60 | -35.80 | -- | 11.83 | -- |
| Organon & Co | 6.35bn | 1.05bn | 5.61bn | 10.00k | 5.35 | 116.20 | 4.34 | 0.8833 | 4.08 | 4.08 | 24.71 | 0.1876 | 0.5603 | 2.18 | 4.24 | 634,700.00 | 9.24 | 16.53 | 11.79 | 20.97 | 59.04 | 65.12 | 16.50 | 26.79 | 1.15 | 2.36 | 0.9945 | 8.25 | 1.44 | -8.52 | 11.56 | -13.83 | 20.72 | -- |
| BridgeBio Pharma Inc | 218.60m | -538.26m | 5.63bn | 550.00 | -- | -- | -- | 25.76 | -3.23 | -3.23 | 1.29 | -5.61 | 0.2964 | -- | -- | 397,449.10 | -74.13 | -72.44 | -90.19 | -89.72 | 98.91 | 94.41 | -250.09 | -1,225.66 | -- | -11.48 | 2.53 | -- | -88.02 | -- | -33.67 | -- | -40.94 | -- |
| Halozyme Therapeutics, Inc. | 862.99m | 318.80m | 5.69bn | 373.00 | 18.49 | 31.98 | 14.19 | 6.59 | 2.42 | 2.42 | 6.54 | 1.40 | 0.4874 | 1.34 | 4.42 | 2,313,644.00 | 18.01 | 18.22 | 19.22 | 21.97 | 78.50 | 79.05 | 36.94 | 39.36 | 5.36 | 966.62 | 0.8941 | 0.00 | 25.62 | 40.43 | 39.31 | -- | 26.82 | -- |
| Exelixis Inc | 1.85bn | 205.05m | 6.09bn | 1.31k | 32.34 | 2.90 | 26.45 | 3.30 | 0.6466 | 0.6466 | 5.84 | 7.21 | 0.621 | 3.12 | 7.78 | 1,409,653.00 | 6.90 | 8.86 | 7.82 | 9.91 | 95.70 | 96.30 | 11.10 | 15.43 | 3.41 | -- | 0.00 | 0.00 | 13.60 | 16.47 | 13.98 | -21.34 | 3.98 | -- |
| Cytokinetics, Inc. | 3.75m | -530.60m | 6.24bn | 423.00 | -- | -- | -- | 1,663.63 | -5.40 | -5.40 | 0.0382 | -3.78 | 0.0044 | -- | 4.08 | 8,869.98 | -62.50 | -43.14 | -69.19 | -47.22 | -- | -- | -14,141.74 | -540.47 | -- | -15.26 | 2.78 | -- | -92.04 | -24.89 | -35.30 | -- | 9.76 | -- |
| Revolution Medicines Inc | 4.57m | -484.27m | 6.50bn | 411.00 | -- | 3.77 | -- | 1,424.03 | -3.76 | -3.76 | 0.035 | 10.46 | 0.0031 | -- | 2.29 | 12,079.37 | -32.48 | -29.76 | -34.18 | -32.59 | -- | -- | -10,606.04 | -606.93 | -- | -- | 0.00 | -- | -67.27 | -10.50 | -75.46 | -- | 38.82 | -- |
| Blueprint Medicines Corp | 282.21m | -288.29m | 6.57bn | 645.00 | -- | 21.15 | -- | 23.29 | -4.82 | -4.82 | 4.59 | 4.96 | 0.2499 | 0.3531 | 6.18 | 430,853.40 | -25.53 | -29.92 | -30.68 | -34.06 | 96.97 | -- | -102.15 | -116.65 | 3.61 | -23.37 | 0.4352 | -- | 22.22 | 41.14 | 9.06 | -- | 4.85 | -- |
| Intra-Cellular Therapies Inc | 513.93m | -110.87m | 6.86bn | 610.00 | -- | 10.57 | -- | 13.35 | -1.15 | -1.15 | 5.34 | 6.15 | 0.6996 | 1.67 | 4.83 | 842,508.20 | -15.09 | -38.27 | -17.67 | -42.77 | 92.82 | -- | -21.57 | -128.42 | 5.00 | -- | 0.00 | -- | 85.51 | -- | 45.49 | -- | -7.22 | -- |
| Jazz Pharmaceuticals PLC | 3.84bn | 330.79m | 6.87bn | 2.80k | 22.49 | 1.86 | 7.02 | 1.79 | 4.85 | 4.85 | 55.49 | 58.65 | 0.3436 | 0.6428 | 5.78 | 1,372,634.00 | 2.99 | 1.48 | 3.36 | 1.62 | 89.53 | 88.79 | 8.69 | 4.26 | 1.90 | 1.87 | 0.607 | 0.00 | 4.78 | 15.19 | 285.14 | -1.49 | -20.04 | -- |
| Viking Therapeutics Inc | 0.00 | -93.72m | 7.39bn | 28.00 | -- | 7.91 | -- | -- | -0.9305 | -0.9305 | 0.00 | 8.47 | 0.00 | -- | -- | 0.00 | -16.76 | -21.91 | -17.52 | -23.04 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -24.73 | -- | -- | -- |
| Bellring Brands Inc | 1.84bn | 191.50m | 7.49bn | 420.00 | 39.92 | -- | 31.66 | 4.06 | 1.44 | 1.44 | 13.84 | -1.90 | 2.40 | 5.40 | 8.71 | 4,389,286.00 | 24.91 | 18.89 | 31.72 | -- | 32.74 | 32.44 | 10.39 | 10.10 | 1.84 | 5.07 | 1.42 | 0.00 | 21.53 | 15.03 | 101.09 | 13.80 | -18.48 | -- |
Data as of May 17 2024. Currency figures normalised to Cytokinetics Inc's reporting currency: US Dollar USD
53.97%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BlackRock Fund Advisorsas of 31 Mar 2024 | 11.19m | 10.70% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 9.73m | 9.31% |
| Fidelity Management & Research Co. LLCas of 31 Mar 2024 | 9.69m | 9.27% |
| T. Rowe Price Investment Management, Inc.as of 31 Mar 2024 | 5.12m | 4.90% |
| SSgA Funds Management, Inc.as of 31 Mar 2024 | 4.52m | 4.32% |
| Bank of America, NA (Private Banking)as of 31 Mar 2024 | 4.24m | 4.05% |
| Wellington Management Co. LLPas of 31 Mar 2024 | 3.98m | 3.81% |
| T. Rowe Price Associates, Inc. (Investment Management)as of 31 Mar 2024 | 2.87m | 2.75% |
| Marshall Wace LLPas of 31 Mar 2024 | 2.56m | 2.45% |
| RTW Investments LPas of 31 Mar 2024 | 2.53m | 2.42% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
